Wedbush Forecasts Prime Medicine FY2029 Earnings
Prime Medicine, Inc. (NYSE:PRME – Free Report) – Analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Prime Medicine in a research report issued on Tuesday, March 18th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($1.27) for the year. Wedbush currently has a “Outperform” rating […]
Prime Medicine, Inc. (NYSE:PRME – Free Report) – Analysts at Wedbush issued their FY2029 earnings per share (EPS) estimates for Prime Medicine in a research report issued on Tuesday, March 18th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($1.27) for the year. Wedbush currently has a “Outperform” rating […]
